Kiromic BioPharma (Kiromic BioPharma) Days Payable : 0.00 (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Kiromic BioPharma Days Payable?

Kiromic BioPharma's average Accounts Payable for the three months ended in Mar. 2024 was $2.07 Mil. Kiromic BioPharma's Cost of Goods Sold for the three months ended in Mar. 2024 was $0.00 Mil.

The historical rank and industry rank for Kiromic BioPharma's Days Payable or its related term are showing as below:

KRBP's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 148.78
* Ranked among companies with meaningful Days Payable only.

Kiromic BioPharma's Days Payable stayed the same from Mar. 2023 (0.00) to Mar. 2024 (0.00). stayed the same

Kiromic BioPharma Days Payable Historical Data

The historical data trend for Kiromic BioPharma's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kiromic BioPharma Days Payable Chart

Kiromic BioPharma Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Payable

Get a 7-Day Free Trial

Kiromic BioPharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Days Payable	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Kiromic BioPharma's Days Payable

For the Biotechnology subindustry, Kiromic BioPharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kiromic BioPharma's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kiromic BioPharma's Days Payable distribution charts can be found below:

* The bar in red indicates where Kiromic BioPharma's Days Payable falls into.

Kiromic BioPharma Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Kiromic BioPharma's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (7.308	+	2.136)	/	2 )	/	0	*	365
=	4.722					/	0	*	365
=	N/A

Kiromic BioPharma's Days Payable for the quarter that ended in Mar. 2024 is calculated as:

	Days Payable (Q: Mar. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Dec. 2023 )	+	Accounts Payable (Q: Mar. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Mar. 2024 )	*	Days in Period
=	( (2.136	+	2)	/	2 )	/	0	*	365 / 4
=	2.068					/	0	*	365 / 4
=	N/A

Kiromic BioPharma Days Payable Related Terms

Thank you for viewing the detailed overview of Kiromic BioPharma's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Kiromic BioPharma (Kiromic BioPharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kiromic BioPharma Inc (OTCPK:KRBP) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

7707 Fannin Street, Suite 140, Houston, TX, USA, 77054

Website

https://www.kiromic.com

Kiromic BioPharma Inc is a biotechnology company. It is an artificial intelligence (AI) driven, end-to-end allogeneic cell therapy company, currently developing the multi-indication allogeneic T cell therapy that exploits the natural potency of the Gamma Delta T cell (GDT) to target solid tumors. The company is a gene-editing which utilizes artificial intelligence and a proprietary neural network platform with a therapeutic focus on immuno-oncology.

Executives

Brian Hungerford	officer: CFO	7707 FANNIN, SUITE 140, HOUSTON TX 77054
Pamela Misajon	director	7707 FANNIN ST, SUITE 140, HOUSTON TX 77054
Michael Catlin	director	7707 FANNIN ST, SUITE 140, HOUSTON TX 77054
Karen Reeves	director	7707 FANNIN, SUITE 140, HOUSTON TX 77054
Francis X Tirelli	director	7707 FANNIN, SUITE 140, HOUSTON TX 77054
Daniel Grant Clark	officer: Interim CFO	7707 FANNIN, SUITE 140, HOUSTON TX 77054
Internati Maurizio Chiriva	director, officer: Chairman, CEO, and President	7707 FANNIN, SUITE 140, HOUSTON TX 77054
Michael Charles Ryan	officer: Chief Technology Officer	7707 FANNIN, SUITE 140, HOUSTON TX 77054
Ignacio Nunez	officer: See Remarks	7707 FANNIN, SUITE 140, HOUSTON TX 77054
Jerry A. Schneider	director	ONE VISION DRIVE, NATICK MA 01760
Michael Nagel	director	C/O VASCULAR SOLUTIONS INC, 6464 SYCAMORE COURT NORTH, MINNEAPOLIS MN 55369
Pietro Bersani	director	C/O FUEL SYSTEMS SOLUTIONS, INC., 780 THIRD AVE. 25TH FLOOR, NEW YORK NY 10017
Scott Dahlbeck	officer: Chief Medical Officer	7707 FANNIN, SUITE 140, HOUSTON TX 77054
Americo Cicchetti	director	7707 FANNIN, SUITE 140, HOUSTON TX 77054
Gianluca Rotino	director, officer: CSIO	7707 FANNIN, SUITE 140, HOUSTON TX 77054